378 related articles for article (PubMed ID: 30791759)
1. Emerging treatments for short bowel syndrome in adult patients.
Billiauws L; Joly F
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):241-246. PubMed ID: 30791759
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
[TBL] [Abstract][Full Text] [Related]
3. Experience with teduglutide treatment for short bowel syndrome in clinical practice.
Pevny S; Maasberg S; Rieger A; Karber M; Blüthner E; Knappe-Drzikova B; Thurmann D; Büttner J; Weylandt KH; Wiedenmann B; Müller VA; Bläker H; Pascher A; Pape UF
Clin Nutr; 2019 Aug; 38(4):1745-1755. PubMed ID: 30145039
[TBL] [Abstract][Full Text] [Related]
4. Medical and surgical management of short bowel syndrome.
Billiauws L; Maggiori L; Joly F; Panis Y
J Visc Surg; 2018 Sep; 155(4):283-291. PubMed ID: 30041905
[TBL] [Abstract][Full Text] [Related]
5. Teduglutide for treatment of adult patients with short bowel syndrome.
Billiauws L; Bataille J; Boehm V; Corcos O; Joly F
Expert Opin Biol Ther; 2017 May; 17(5):623-632. PubMed ID: 28293969
[TBL] [Abstract][Full Text] [Related]
6. What's new in short bowel syndrome?
Billiauws L; Corcos O; Joly F
Curr Opin Clin Nutr Metab Care; 2018 Jul; 21(4):313-318. PubMed ID: 29702489
[TBL] [Abstract][Full Text] [Related]
7. Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.
Iturrino J; Camilleri M; Acosta A; O'Neill J; Burton D; Edakkanambeth Varayil J; Carlson PJ; Zinsmeister AR; Hurt R
JPEN J Parenter Enteral Nutr; 2016 Nov; 40(8):1089-1095. PubMed ID: 26223941
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
Jeppesen PB
JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
[TBL] [Abstract][Full Text] [Related]
10. Short bowel syndrome: highlights of patient management, quality of life, and survival.
Kelly DG; Tappenden KA; Winkler MF
JPEN J Parenter Enteral Nutr; 2014 May; 38(4):427-37. PubMed ID: 24247092
[TBL] [Abstract][Full Text] [Related]
11. Parenteral Nutrition and Intestinal Failure.
Bielawska B; Allard JP
Nutrients; 2017 May; 9(5):. PubMed ID: 28481229
[TBL] [Abstract][Full Text] [Related]
12. Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up.
Zaczek Z; Jurczak-Kobus P; Panczyk M; Braszczyńska-Sochacka J; Majewska K; Kunecki M; Dąbrowska K; Sobocki J
Nutrients; 2022 Apr; 14(8):. PubMed ID: 35458196
[TBL] [Abstract][Full Text] [Related]
13. Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects.
Vipperla K; O'Keefe SJ
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):683-7. PubMed ID: 24134154
[TBL] [Abstract][Full Text] [Related]
14. Understanding short bowel syndrome: Current status and future perspectives.
Massironi S; Cavalcoli F; Rausa E; Invernizzi P; Braga M; Vecchi M
Dig Liver Dis; 2020 Mar; 52(3):253-261. PubMed ID: 31892505
[TBL] [Abstract][Full Text] [Related]
15. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
Jeppesen PB; Pertkiewicz M; Messing B; Iyer K; Seidner DL; O'keefe SJ; Forbes A; Heinze H; Joelsson B
Gastroenterology; 2012 Dec; 143(6):1473-1481.e3. PubMed ID: 22982184
[TBL] [Abstract][Full Text] [Related]
16. Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.
Seidner DL; Schwartz LK; Winkler MF; Jeejeebhoy K; Boullata JI; Tappenden KA
JPEN J Parenter Enteral Nutr; 2013 Mar; 37(2):201-11. PubMed ID: 23343999
[TBL] [Abstract][Full Text] [Related]
17. New approaches to the treatments of short bowel syndrome-associated intestinal failure.
Jeppesen PB
Curr Opin Gastroenterol; 2014 Mar; 30(2):182-8. PubMed ID: 24406477
[TBL] [Abstract][Full Text] [Related]
18. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
[TBL] [Abstract][Full Text] [Related]
19. Teduglutide for the treatment of short bowel syndrome - a safety evaluation.
Kochar B; Herfarth HH
Expert Opin Drug Saf; 2018 Jul; 17(7):733-739. PubMed ID: 29848084
[TBL] [Abstract][Full Text] [Related]
20. ESPEN guidelines on chronic intestinal failure in adults.
Pironi L; Arends J; Bozzetti F; Cuerda C; Gillanders L; Jeppesen PB; Joly F; Kelly D; Lal S; Staun M; Szczepanek K; Van Gossum A; Wanten G; Schneider SM;
Clin Nutr; 2016 Apr; 35(2):247-307. PubMed ID: 26944585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
